Hypertension in aging patients

References

• Leenen FHH, Dumais J, McInnis NH et al. Results of the Ontario Survey on the prevalence and control of hypertension. CMAJ178(11), 1441–1449 (2008).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet365, 217–223 (2005).
   PubMed Web of Science ®Google Scholar
• Blood pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Br. Med. J.336, 1121–1127 (2008).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet355, 865–872 (2000).
   PubMed Web of Science ®Google Scholar
• Franklin SS, Jacobs MJ, Wong ND, L’Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives. Hypertension37, 869–874 (2001).
   PubMed Web of Science ®Google Scholar
• Vasan RS, Beiser A, Seshadri S et al. Residual lifetime risk for developing hypertension in middle-aged women and men. JAMA287, 1003–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J. Hypertens.21, 707–716 (2003).
   PubMed Web of Science ®Google Scholar
• Oates DJ, Berlowitz DR, Glickman ME, Silliman RA, Borzecki AM. Blood pressure and survival in the oldest old. J. Am. Geriatr. Soc.55, 383–388 (2007).
   PubMed Web of Science ®Google Scholar
• Laurent S, Cockcroft J, van Bortel L et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur. Heart J.27, 2588–2605 (2006).
   PubMed Web of Science ®Google Scholar
• Messerli FH, Ventura HO, Glade LB et al. Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet2, 983–986 (1983).
   PubMed Web of Science ®Google Scholar
• Mimran A, Ribstein J, Jover B. Aging and sodium homeostasis. Kidney Int.37(Suppl.), S107–S113 (1992).
   Google Scholar
• Henry RMA, Kostense PJ, Spijkerman AMW et al. Arterial stiffness increases with deteriorating glucose tolerance status. The Hoorn Study. Circulation107, 2089–2095 (2003).
   PubMed Web of Science ®Google Scholar
• Kithas PA, Supiano MA. Hypertension and chronic kidney disease in the elderly. Adv. Chronic Kidney Dis.17(4), 341–347 (2010).
   Google Scholar
• Rowlands DB, Stallard TJ, Littler WA. Continuous ambulatory monitoring of blood pressure and assessment of cardiovascular reflexes in the elderly hypertensive. J. Hypertens.2, 615–622 (1984).
   PubMedGoogle Scholar
• O’Rourke MF. From theory into practice: arterial haemodynamics in clinical hypertension. J. Hypertens.20, 1901–1915 (2002).
   Google Scholar
• Myers MG, Tobe SW, McKay DW et al. New algorithm for the diagnosis of hypertension. Am. J. Hypertens18, 1369–1374 (2005).
   PubMed Web of Science ®Google Scholar
• Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N. Engl. J. Med.354, 2368–2374 (2006).
   PubMed Web of Science ®Google Scholar
• Manios ED, Koroboki EA, Tsivgoulis GK et al. Factors influencing white-coat effect. Am. J. Hypertens.21, 153–158 (2008).
   PubMed Web of Science ®Google Scholar
• Verberk WJ, Kessels AGH, de Leeuw PW. Prevalence, causes, and consequences of masked hypertension: a meta-analysis. Am. J. Hypertens.21, 969–975 (2008).
   PubMed Web of Science ®Google Scholar
• Friedman O, Logan AG. Can nocturnal hypertension predict cardiovascular risk? Integrated BP Control2, 25–37 (2009).
   Google Scholar
• Boggia J, Li Y, Thijs L et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet370, 1219–1229 (2007).
   PubMed Web of Science ®Google Scholar
• Ben-Dov IZ, Kark JD, Ben-Ishay D et al. Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. Hypertension49, 1235–1241 (2007).
   PubMed Web of Science ®Google Scholar
• Schillaci G, Verdecchia P, Borgioni C et al. Predictors of diurnal blood pressure changes in 2042 subjects with essential hypertension. J. Hypertens.14, 1167–1173 (1996).
   Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25, 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Black HR, Cannon CP et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation115, 2761–2788 (2007).
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol. Circulation106, 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Jackson R, Lawes CMM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet365, 434–441 (2005).
   PubMed Web of Science ®Google Scholar
• D’Agostino RB Sr, Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation117, 743–753 (2008).
   PubMed Web of Science ®Google Scholar
• D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; for the CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction score. Results of a multiple ethnic groups investigation. JAMA286, 180–187 (2001).
   PubMed Web of Science ®Google Scholar
• Koller MT, Steyerberg EW, Wolber M et al. Validity of the Framingham point scores in the elderly: results from the Rotterdam study. Am. Heart J.154, 87–93 (2007).
   PubMedGoogle Scholar
• Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among US adults. Findings from the National Health & Nutrition Examination Survey III. J. Am. Coll. Cardiol.43, 1791–1796 (2004).
   PubMed Web of Science ®Google Scholar
• Quinn RR, Hemmelgarn BR, Padwal RS et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1 – blood pressure measurement, diagnosis and assessment of risk. Can. J. Cardiol.26(5), 241–248 (2010).
   Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension42, 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Gona P, Larson MG et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med.355, 2631–2639 (2006).
   PubMed Web of Science ®Google Scholar
• Kennedy RL, Chokkalingham K, Srinivasan R. Obesity in the elderly: who should we be treating, and why, and how? Curr. Opin. Clin. Nutr. Metab. Care7, 3–9 (2004).
   PubMed Web of Science ®Google Scholar
• Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure. A meta-analysis of randomized controlled trials. Hypertension42, 878–884 (2003).
   PubMed Web of Science ®Google Scholar
• Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized controlled trials. Ann. Intern. Med.136, 493–503 (2002).
   PubMed Web of Science ®Google Scholar
• Brennan P, Pescatello LS, Bohannon RW et al. Time spent moving as related to systolic blood pressure among older women. Prev. Cardiol.8, 160–164 (2005).
   Google Scholar
• Ferrier KE, Waddell TK, Gatzka CD et al. Aerobic exercise training does not modify large-artery compliance in isolated systolic hypertension. Hypertension38, 222–226 (2001).
   PubMed Web of Science ®Google Scholar
• Appel LJ, Moore TJ, Obarzanek E et al. A clinical trial of the effects of dietary patterns on blood pressure. N. Engl. J. Med.336, 1117–1124 (1997).
   PubMed Web of Science ®Google Scholar
• Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G; for the DASH-Sodium Trial Collaborative Research Group. Effects of the dietary approaches to stop hypertension (DASH) diet on the pressure–natriuresis relationship. Hypertension42, 8–13 (2003).
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Dietary Reference Intakes: Water, Potassium, Sodium, Chloride, and Sulfate. [Appendix F: Dietary Intake Data for Adults from Ten Provinces in Canada, 1990–1997]. National Academy Press, Washington, DC, USA (2004).
   Google Scholar
• Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure. Age and pressure change over time. Hypertension18(1), 67–71 (1991).
   PubMed Web of Science ®Google Scholar
• Cappuccio FP, Markandu ND, Carney C, Sagnella GA, MacGregor GA. Double-blind randomized trial of modest salt restriction in older people. Lancet350, 850–854 (1997).
   PubMed Web of Science ®Google Scholar
• Hooper L, Bartlett C, Davey Smith G, Ebrahim S. Systematic review of long term effects of advice to reduce dietary salt in adults. Br. Med. J.325, 628–636 (2002).
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens.27, 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J. Hypertens.27, 1509–1520 (2009).
   PubMed Web of Science ®Google Scholar
• Hackam DG, Khan NA, Hemmelgarn BR et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 – therapy. Can. J. Cardiol.65(5), 249–258 (2010).
   Google Scholar
• National Collaborating Centre for Chronic Conditions. Hypertension: Management in Adults in Primary Care: Pharmacological Update. Royal College of Physicians, London, UK (2006).
   Google Scholar
• Amery A, Birkenhäger W, Brixko P et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. EWPHE (European Working Party on High Blood Pressure in the Elderly) results: sub-group analysis based on entry stratification. J. Hypertens.4(Suppl. 6), S642–S647 (1986).
   Google Scholar
• Gueyffier F, Bulpitt C, Boissel J-P et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet353, 793–796 (1999).
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE et al.; for the HYVET trial. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med.358, 1887–1898 (2008).
   PubMed Web of Science ®Google Scholar
• Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM et al. Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J. Hypertens.28, 1366–1372 (2010).
   PubMed Web of Science ®Google Scholar
• Butt TF, Branch RL, Beesley L, Martin U. Managing hypertension in the very elderly: effect of adverse drug reactions (ADRs) on achieving targets. J. Hum. Hypertens.24, 514–518 (2010).
   Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiologic studies. Br. Med. J.338, b1665 (2009).
   PubMed Web of Science ®Google Scholar
• Williams B, Lacy PS, Thom SM et al.; the CAFÉ Investigators, for the Anglo–Scandinavian Cardiac Outcomes Trial (ASCOT). Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation113, 1213–1225 (2006).
   PubMed Web of Science ®Google Scholar
• Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial Cognitive Function Assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol.7, 683–689 (2008).
   PubMed Web of Science ®Google Scholar
• Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet1(8533), 581–584 (1987).
   PubMed Web of Science ®Google Scholar
• Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch. Intern. Med.159, 2004–2009 (1999).
   PubMed Web of Science ®Google Scholar
• Kannel WB, Vasan RS. Aggressive lowering of blood pressure. Lancet368, 627–628 (2006).
   Google Scholar
• Fagard RH, Staessen JA, Thijs L et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch. Intern. Med.167(17), 1884–1891 (2007).
   PubMedGoogle Scholar
• Yusuf S, Diener H-C, Sacco RL et al.; for the PRoFESS study group. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med.359(12), 1225–1237 (2008).
   PubMed Web of Science ®Google Scholar
• Cushman WC, Evans GW, Bylington RP et al.; ACCORD study group. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med.362(17), 1575–1585 (2010).
   PubMed Web of Science ®Google Scholar
• Sleight P, Redon J, Verdecchia P et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J. Hypertens.27(7), 1360–1369 (2009).
   PubMed Web of Science ®Google Scholar
• Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann. Intern. Med.144(22), 884–893 (2006).
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical appraisal. J. Hypertens.27, 923–934 (2009).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Staessen JA, Angeli F et al.; Cardio-Sis Investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomized trial. Lancet374, 525–533 (2009).
   PubMed Web of Science ®Google Scholar
• Tu K, Campbell NRC, Duong-Hua M, McAlister FA. Hypertension management in the elderly has improved. Ontario prescribing trends, 1994 to 2002. Hypertension45, 1113–1118 (2005).
   PubMed Web of Science ®Google Scholar
• Tu K, Chen Z, Lipscombe LL. Mortality among patients with hypertension from 1995 to 2005: a population-based study. CMAJ178(11), 1436–1440 (2008).
   PubMed Web of Science ®Google Scholar
• Singer GM, Izhar M, Black HR. Guidelines for hypertension: are quality-assurance measures on target? Hypertension43, 198–202 (2004).
   PubMed Web of Science ®Google Scholar
• Julius S, Nesbitt SD, Egan BM et al.; for the Trial of Preventing Hypertension (TROPHY) study investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med.354, 1685–1697 (2006).
   PubMed Web of Science ®Google Scholar
• Lüders S, Schrader J, Berger J et al.; PHARAO study group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League. J. Hypertens.26, 1487–1496 (2008).
   PubMed Web of Science ®Google Scholar